Objectives: To determine antibiotic susceptibility of isolates of Streptococcus pneumoniae (n " 573) and Haemophilus influenzae (n " 345) collected in 2014-16 from Bulgaria, Romania, Serbia and Croatia.
Introduction
Community-acquired pneumonia (CAP) continues to pose a major challenge for healthcare systems both because of the sheer number of cases and because initial antimicrobial treatment remains empirical despite advances in diagnostic techniques. 1, 2 Professional societies in many countries have published recommendations to help guide empirical treatment and to encourage appropriate use of antibiotics. Unfortunately, there is evidence that these guidelines often do not take into account antimicrobial resistance patterns, which can vary greatly across geographic regions. 3 A recent WHO study emphasizes that this must change and urges international projects to support the many countries in the world that lack the infrastructure to systematically collect resistance data. 3 The Survey of Antibiotic Resistance (SOAR) is an international antimicrobial resistance surveillance study of key respiratory pathogens conducted in Europe, the Middle East, Africa, Latin America, Asia-Pacific and Commonwealth of Independent States countries since 2002. Data recently published from this study confirm large differences in antibiotic resistance in respiratory pathogens even within the same region of the world, such as Asia, 4 Africa 5 and the Gulf states, 6 and underscores the importance of monitoring and reporting national and even local resistance rates. For this report, recent SOAR data from hospitals in Bulgaria, Croatia, Romania and Serbia were analysed to provide a picture of the current state of antimicrobial susceptibility of Streptococcus pneumoniae and Haemophilus influenzae, two important bacterial pathogens associated with CAP and other respiratory tract infections.
Materials and methods

Collaborating centres
The following centres took part in the study: one from Bulgaria (University Hospital 'Tsaritsa Yoanna' ISUL), two from Romania (Spitalul Clinic Dr Victor Babes and Spitalul Clinic de Urgenta Pentru Copii Grigore Alexandrescu), one from Serbia (Institute of Public Health of Vojvodina) and one site from Croatia (Clinical Hospital Centre, Zagreb).
Isolates of H. influenzae and S. pneumoniae from community-acquired respiratory tract infections were sent to a central laboratory (International Health Management Associates, Inc., Schaumburg, IL, USA) where they were sub-cultured and re-identified. H. influenzae were re-identified by MALDI-TOF MS methodology and S. pneumoniae identity was confirmed by optochin susceptibility and bile solubility. b-Lactamase production was determined for each H. influenzae isolate by a chromogenic cephalosporin (nitrocefin) disc method. Duplicate isolates from the same patient were excluded from the analysis. The following data were obtained from each patient: specimen source (direct respiratory specimen or blood sample from confirmed CAP infection), age and gender.
Susceptibility testing
Isolates were evaluated for antibiotic susceptibility using broth microdilution methodology recommended by CLSI. 7 Both pathogens were assessed for susceptibility to amoxicillin, amoxicillin/ clavulanic acid (2:1), azithromycin, cefaclor, ceftriaxone, cefuroxime, clarithromycin, erythromycin, levofloxacin, moxifloxacin and trimethoprim/sulfamethoxazole (1:19) . S. pneumoniae was also tested for susceptibility to penicillin and H. influenzae was additionally tested for susceptibility to ampicillin.
Susceptibility to the study drugs was calculated based on CLSI breakpoints, EUCAST breakpoints and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. [8] [9] [10] These breakpoints are shown in Table 1 .
Quality control and data analysis
Quality control strains S. pneumoniae ATCC 49619, Escherichia coli ATCC 25922, H. influenzae ATCC 49247, H. influenzae ATCC 49766 and E. coli ATCC 32518 were included on each day of testing. Results of susceptibility testing were accepted if the results of the control strains were within published limits. Differences in susceptibility between age groups, source of infection and penicillin susceptibility (S. pneumoniae only) were assessed for statistical significance (where n 20) with Fisher's exact test using XLSTAT version 2011.1.05. A P value ,0.05 was considered statistically significant.
Results
S. pneumoniae isolates
A total of 573 S. pneumoniae isolates were collected from five centres in Bulgaria, Romania, Serbia and Croatia from 2014-16. Most pneumococci came from middle ear effusion (n " 147; 25.7%) and sputum (n " 131; 22.9%). Less frequently, isolates were from endotracheal aspirate (n " 82; 14.3%), sinuses (n " 29; 5.1%), blood (n " 20; 3.5%) and bronchoalveolar lavage (n " 6; 1.0%). A large proportion of isolates were from an undisclosed respiratory source (n " 158; 27.6%). Most isolates (n " 367; 64.0%)
came from children (aged 12 years), 165 (28.8%) were from adult patients (13-64 years old) and 41 (7.2%) were from elderly patients (aged 65 years). Summary MIC and susceptibility data for all 573 S. pneumoniae isolates broken down by country of origin are shown in Table 2 . MIC distribution data are given in Table 3 .
S. pneumoniae susceptibility in Bulgaria
By CLSI, penicillin intravenous (iv) (non-meningitis) breakpoints all 164 S. pneumoniae isolates from Bulgaria were penicillin susceptible, but using CLSI penicillin oral breakpoints or EUCAST breakpoints 86.6% (142/164) were penicillin susceptible. The S. pneumoniae were 100% susceptible to amoxicillin, amoxicillin/ clavulanic acid, levofloxacin and moxifloxacin by all breakpoints. Ceftriaxone susceptibility was 100% by CLSI and PK/PD breakpoints, but reduced to 95.1% (156/164) with the lower EUCAST breakpoints. Cefuroxime susceptibility was 93.3% (153/164) by CLSI or PK/PD breakpoints and 92.1% by EUCAST breakpoints (151/164). Cefaclor, on the other hand, had good activity by CLSI standards (93.3% susceptible, 153/164) but was very poorly active (9.1% susceptible, 15/164) by PK/PD breakpoints, with no isolates appearing susceptible by EUCAST breakpoints ( Table 2) .
Rates of susceptibility to clarithromycin and erythromycin were 75.6% (124/164) and 75.0% (123/164) by all breakpoints, respectively. Azithromycin susceptibility was 75.6% by CLSI breakpoints but lower rates of susceptibility were seen using EUCAST (74.4%) and PK/PD (68.9%) breakpoints. Trimethoprim/sulfamethoxazole susceptibility was similar to the macrolides at 76.8% susceptible (126/164) by CLSI or PK/PD breakpoints and 78.7% (129/164) susceptible by EUCAST breakpoints.
Antimicrobial susceptibility was compared by type of specimen and patient age with no significant difference observed (data not shown).
S. pneumoniae susceptibility in Romania
Susceptibility to penicillin was noted in 71.6% of pneumococci using CLSI penicillin iv (non-meningitis) breakpoints but by CLSI penicillin oral breakpoints or EUCAST breakpoints only 22.3% (51/229) of S. pneumoniae were penicillin susceptible. The S. pneumoniae were 100% susceptible to levofloxacin and moxifloxacin by all breakpoints. Ceftriaxone susceptibility was seen in 82.1% of pneumococci using CLSI and PK/PD breakpoints, but was much less susceptible by EUCAST breakpoints (46.3%, 106/229). Amoxicillin and amoxicillin/clavulanic acid susceptibility was seen in 79.5% (182/229) and 85.2% (195/229) at high-dose PK/PD breakpoints, respectively, but reduced to 73.4% (168/229) and 76.9% (176/229), respectively, by CLSI or low-dose PK/PD breakpoints. The other antimicrobials showed very poor susceptibility, with cefuroxime being the most potent at only 43.2% (99/229) susceptibility (Table 2) .
A comparison of antimicrobial susceptibility by isolate specimen source from Romania is shown in Figure 1 . Differences were observed, with susceptibility generally higher in sputum than other specimen sources. When comparing age groups, the only significant difference between isolates from children (n " 195, 18.5% susceptible) and from adults (n " 25, 40.0% susceptible) was for penicillin (P " 0.019). 
S. pneumoniae susceptibility in Serbia
Susceptibility to penicillin was noted in 70.1% of pneumococci from Serbia using CLSI penicillin iv (non-meningitis) breakpoints but by CLSI penicillin oral breakpoints or EUCAST breakpoints only 21.8% (19/87) were penicillin susceptible. All the pneumococci tested were susceptible to levofloxacin and moxifloxacin by all breakpoints. Ceftriaxone showed 82.8% (72/87) susceptibility by CLSI and PK/PD breakpoints, but only 40.2% (35/87) susceptibility by EUCAST breakpoints. Amoxicillin or amoxicillin/clavulanic acid susceptibility was 73.6% (64/87) and 86.2% (75/87) at high-dose PK/PD breakpoints, respectively, but reduced to 60.9% (53/87) and 66.7% (58/87), respectively, by CLSI or low-dose PK/PD breakpoints. As seen in Romania, the other antimicrobials showed poor activity but in Serbia trimethoprim/sulfamethoxazole was most potent, although only 46.0% (40/87) of isolates were susceptible ( Table 2) .
Insufficient isolates were obtained to analyse antimicrobial susceptibility by specimen source or age.
S. pneumoniae susceptibility in Croatia
Susceptibility to penicillin was noted in 73.1% of pneumococcal isolates from Croatia using CLSI penicillin iv (non-meningitis) breakpoints, and by CLSI penicillin oral breakpoints or EUCAST breakpoints 57.0% (53/93) of S. pneumoniae were penicillin susceptible. All pneumococci were susceptible to levofloxacin and moxifloxacin by all breakpoints. Ceftriaxone showed 90.3% (84/93) susceptibility by CLSI and PK/PD breakpoints but 66.7% of isolates were susceptible by EUCAST breakpoints. Amoxicillin and amoxicillin/clavulanic acid susceptibility was 76.3% (71/93) and 90.3% (84/93) at high-dose PK/PD breakpoints, respectively, but reduced to 73.1% (68/93) and 74.2% (69/93), respectively, by CLSI or low-dose PK/PD breakpoints. Although the other antimicrobials had greater activity against isolates from Croatia than against those from Serbia or Romania, these agents were less active than against isolates from Bulgaria. In Croatia, the activity of other antimicrobials ranged from 0% for cefaclor by EUCAST breakpoints to 66.7% (62/93) for cefuroxime by CLSI or PK/PD breakpoints ( Table 2) .
Insufficient isolates were obtained to analyse antimicrobial susceptibility by specimen source. No difference was observed with patient age (data not shown).
Antimicrobial susceptibility of S. pneumoniae by penicillin susceptibility Amoxicillin/clavulanic acid was tested at a 2:1 amoxicillin to clavulanic acid ratio; breakpoints are expressed as the amoxicillin component. PK/PD breakpoints based on high dose (4 g of amoxicillin with 250 mg of clavulanate per day for adults) shown in parenthesis, 10 which is the same as CLSI for H. influenzae and one dilution higher for S. pneumoniae. CLSI oral breakpoints. Susceptibility to other antimicrobial agents was compared among these three sub-groups ( Figure 2 ). Among PSSP isolates, susceptibility to the fluoroquinolones, amoxicillin, amoxicillin/clavulanic acid and the cephalosporins was 100%, and ranged from 82% to 86% for the macrolides and trimethoprim/ sulfamethoxazole (using CLSI criteria). Susceptibility was significantly lower in PISP isolates to the oral cephalosporins (76% for cefuroxime and 31% for cefaclor) as well as macrolides and trimethoprim/sulfamethoxazole (32%-50%). Antimicrobial activity was further reduced in PRSP isolates and was significantly lower than in PSSP and PISP isolates for all studied antimicrobials except the fluoroquinolones (for which susceptibility was 100% in all subsets). Susceptibility of PRSP isolates was 0%-12% for the oral cephalosporins, macrolides and trimethoprim/sulfamethoxazole, 39% for amoxicillin, 46% for amoxicillin/clavulanic acid and 67% for ceftriaxone.
H. influenzae isolates
A total of 345 H. influenzae isolates were collected from five centres in Bulgaria, Romania, Serbia and Croatia from 2014 to 2016. Infection origins of the isolates included sputum (n " 87; 25.2%), endotracheal aspirate (n " 69, 20.0%), middle ear effusion (n " 53, 15.4%), bronchoalveolar lavage (n " 32; 9.3%), sinuses (n " 26; 7.5%) and blood (n " 2, 0.6%). Seventy-six isolates (22.0%) were from an undisclosed respiratory source. Most isolates (n " 162; 47.0%) came from children, 143 (41.4%) were from adult patients and 38 (11.0%) were from elderly patients. Two isolates were from patients where age was not provided. Twenty-nine isolates were b-lactamase-positive (29/345; 8.4%) and 316 (91.6%) were b-lactamase-negative. None was b-lactamase-negativeampicillin-resistant (BLNAR) by CLSI breakpoints (ampicillin MIC 4 mg/L) or EUCAST breakpoints (ampicillin MIC 2 mg/L). Summary MIC and susceptibility data for all 345 H. influenzae isolates broken down by country of origin are shown in Table 4 . MIC distribution data are given in Table 5 .
H. influenzae susceptibility in Bulgaria
All isolates were susceptible to amoxicillin/clavulanic acid, ampicillin, ceftriaxone, levofloxacin and moxifloxacin by all three breakpoint (where available) guidelines. Amoxicillin susceptibility was 100% by high-dose PK/PD breakpoints but 95.9% (70/73) by lowdose PK/PD or EUCAST breakpoints. Cefuroxime susceptibility was 100% by CLSI, but this reduced to 89.0% (65/73) by PK/PD and 0% by EUCAST criteria. Even more dramatically, cefaclor susceptibility was 100% by CLSI but 0% by PK/PD breakpoints (no EUCAST breakpoints are available for cefaclor). For azithromycin the same breakpoint guideline variability was observed, with full susceptibility by CLSI and 0% by PK/PD or EUCAST breakpoints. This breakpoint difference was also shown with clarithromycin susceptibility, although activity was much lower: 58.9% susceptible (43/73) by CLSI and 0% susceptible by PK/PD or EUCAST. Trimethoprim/sulfamethoxazole susceptibility was 56.2% (41/73) by all three breakpoint categories.
Antimicrobial susceptibility was compared by specimen and age with no significant difference observed (data not shown).
H. influenzae susceptibility in Romania
All isolates were susceptible to ceftriaxone, levofloxacin and moxifloxacin by all three breakpoint guidelines. Susceptibility to amoxicillin/clavulanic acid was 98.6% (141/143) by CLSI breakpoints and high-dose PK/PD breakpoints but 94.4% (135/143) by low-dose PK/PD or EUCAST breakpoints. Susceptibility to amoxicillin was 83.2% (119/143) by high-dose PK/PD and 81.8% (117/143) by lowdose PK/PD or EUCAST breakpoints.
Susceptibility to cefuroxime (oral) was 99.3% (142/143) by CLSI, but this reduced to 69.9% (100/143) by PK/PD and 0% by EUCAST. As observed in Bulgaria, susceptibility to cefaclor was much higher by CLSI breakpoints (86.0%, 123/143) than by PK/PD (0%); no EUCAST breakpoints are available. This variability was also observed for susceptibility to azithromycin: 99.3% (142/143) by CLSI and 0% by PK/PD or EUCAST breakpoints. In addition, this was shown with susceptibility to clarithromycin, although activity was much lower: 59.4% (85/143) by CLSI and 0% by PK/PD or EUCAST breakpoints. Susceptibility to trimethoprim/sulfamethoxazole was 64.3% (92/143) by all three breakpoint categories.
Antimicrobial susceptibility was compared by age with no significant difference observed (data not shown). A comparison by specimen source showed a significant difference (P " 0.03) only for cefaclor between isolates from endotracheal aspirate (n " 59, 91.5% susceptible) and sputum (n " 32, 71.9% susceptible). Torumkuney et al. 25  10  13  21  55  54  clarithromycin  229  50  12  1  20 146  erythromycin  229  1  58  3  2  165  levofloxacin  229  4  220  5  moxifloxacin  229  21  163  44  1  penicillin  229  51  13  10  13  26  51  53  12  SXT  229  1  54  11  14  1  19 129  Serbia  amoxicillin  87  8  12  7  3  2  8  13  11  22  1  AMC  87  20  3  6  3  3  11  12  17  12  azithromycin  87  2  26  2  57  cefaclor  87  1  5  16  3  7  55  ceftriaxone  87  17  5  1  8  4  37  11  3  1  cefuroxime (oral)  87  22  7  3  3  2  28  22  clarithromycin  87  25  5  57  erythromycin  87  1  28  1  57  levofloxacin  87  84  3  moxifloxacin  87  13  65  9  penicillin  87  19  3  5  5  6  23  23  3  SXT  87  22  7  11  6  41  Croatia  amoxicillin  93  32  21  2  3  1  6  3  3  21  1  AMC  93  51  3  2  2  2  4  3  2  15  8  1  azithromycin  93  1  6  41  4  1  40  cefaclor  93  1  3  11  40  2  5  31  ceftriaxone  93  1  44  7  3  3  4  22  8  1  cefuroxime (oral)  93  53  3  1  5  3  4  24  clarithromycin  93  45  7  1  40  erythromycin  93  51  1  41  levofloxacin  93  1  91  1  moxifloxacin  93  16  69  8  penicillin  93  53  2  3  1  6  3  24  1  SXT  93  46  6  7  1  33 AMC, amoxicillin/clavulanate; SXT, sulfamethoxazole/trimethoprim. 
H. influenzae susceptibility in Croatia
In Croatia, H. influenzae susceptibility in 99 isolates was 100% for ceftriaxone, levofloxacin and moxifloxacin by all three breakpoint guidelines. Susceptibility to amoxicillin/clavulanic acid was also 100% by CLSI breakpoints and high-dose PK/PD breakpoints but 97.0% (96/99) by low-dose PK/PD or EUCAST breakpoints. Susceptibility to amoxicillin was 91.9% (91/99) by high-dose PK/PD and 88.9% (88/99) by low-dose PK/PD or EUCAST breakpoints. Susceptibility of isolates to cefuroxime (oral) was 99.0% (98/99) by CLSI criteria, but this reduced to 68.7% (68/99) by PK/PD and 1.0% (1/99) by EUCAST breakpoints. As observed in Bulgaria, Romania and Serbia, susceptibility of isolates to cefaclor was much higher by CLSI breakpoints (81.8%, 81/99) than by PK/PD (3.0%, 3/99); no EUCAST breakpoints are available. This variability was also observed with azithromycin: 98.0% (97/99) by CLSI and 1.0% (1/99) by PK/PD or EUCAST breakpoints. This was also shown with Percentage susceptibility rates (with 95% CI) for antimicrobials against S. pneumoniae from Romania according to specimen source. *Susceptibility to ceftriaxone and amoxicillin was significantly lower in isolates from middle ear than from endotracheal aspirate (P " 0.002 and 0.006, respectively) or sputum (P " 0.023 and 0.004, respectively). **Susceptibility to amoxicillin/clavulanic acid was significantly lower in isolates from middle ear than from endotracheal aspirate (P " 0.003). ***Susceptibility to cefuroxime (oral), cefaclor, penicillin or the macrolides was significantly lower in isolates from middle ear than from sputum (P , 0.05) and lower in isolates from endotracheal aspirate than from sputum (P , 0.01). ****Susceptibility to trimethoprim/sulfamethoxazole was significantly lower in isolates from middle ear than from sputum (P " 0.005).
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susceptibility to clarithromycin, although activity was much lower with clarithromycin: 43.4% (43/99) by CLSI, 0% by PK/PD and 1.0% (1/99) by EUCAST breakpoints. Susceptibility to trimethoprim/ sulfamethoxazole was 72.7% (72/99) by all three breakpoint categories. Antimicrobial susceptibility was compared by specimen and age with no significant difference observed (data not shown).
Discussion
Increasing antimicrobial resistance can significantly affect empirical treatment options, which are essential for communityacquired respiratory tract infections. SOAR surveys antimicrobial resistance in key respiratory pathogens and is currently conducted throughout the Middle East, Africa, Latin America, Asia-Pacific and the Commonwealth of Independent States countries and has been running since 2002. It was established to provide information on local resistance patterns among the two most common pulmonary pathogens, S. pneumoniae and H. influenzae. S. pneumoniae showed substantial variation in antimicrobial resistance across the four countries studied. Susceptibility was highest in Bulgaria (75% susceptible to all studied antimicrobials using CLSI breakpoints), lower in Croatia (55%-65% for macrolides, cephalosporins except ceftriaxone, oral penicillin and trimethoprim/sulfamethoxazole) and lowest in Romania and Serbia (20%-45% for macrolides, cephalosporins except ceftriaxone, oral penicillin and trimethoprim/sulfamethoxazole). In Bulgaria, cefuroxime, penicillin and the fluoroquinolones were active against .80% of isolates by all breakpoint criteria, whereas in Croatia, Romania and Serbia only the fluoroquinolones exceeded this threshold (100% susceptible).
In Bulgaria, higher non-susceptibility rates were reported in a recent study, with 47% non-susceptibility to oral penicillin, 44% to erythromycin and 45% to trimethoprim/sulfamethoxazole by EUCAST criteria. 11 However, these S. pneumoniae isolates included a large proportion of invasive isolates from CSF and blood in addition to the isolates from respiratory infections. On the other hand, a report on S. pneumoniae isolates from upper respiratory Percentage susceptibility rates (with 95% CI, using CLSI criteria) for antimicrobials against all S. pneumoniae according to susceptibility to penicillin. *Penicillin-susceptible S. pneumoniae (PSSP) and penicillin-intermediate S. pneumoniae (PISP) were significantly more susceptible to amoxicillin, amoxicillin/ clavulanic acid or ceftriaxone than penicillin-resistant (PRSP) isolates (P , 0.0001). **PSSP were significantly more susceptible to macrolides, cefuroxime (oral), cefaclor or trimethoprim/sulfamethoxazole than PISP (P , 0.0001) and PISP were significantly more susceptible than PRSP (P , 0.0001).
SOAR: Bulgaria, Romania, Serbia and Croatia 2014-16 Torumkuney et al. infections in children collected in 2014 in Bulgaria reported susceptibility rates more similar to the current study, 80% for penicillin and 70% for azithromycin, although trimethoprim/sulfamethoxazole susceptibility was lower (45%). 12 For Romania, high rates of resistance to macrolides and penicillin (similar to our findings) were described in a recent study of isolates from children with community-acquired alveolar pneumonia admitted to one hospital in central Romania between 2009 and 2014. 13 Nonsusceptibility rates of 89.7% for penicillin and 69.3% for erythromycin were found. Similar results were reported for nasopharyngeal isolates carried by healthy children in Romania from 2011 to 2013, which showed erythromycin resistance rates of 72.5% and non-susceptibility to penicillin of 71.6%.
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14 For Serbia, a recently published study of 190 S. pneumoniae isolates from tracheal aspirates of children hospitalized in 2012-14 with respiratory tract infections from one clinical centre reported 21.6% susceptibility to erythromycin and 36.0% to trimethoprim/sulfamethoxazole (even lower than the rates found in the current study), 15 whereas a study of isolates from 2013 from patients with upper respiratory tract infections in one district in Serbia found rates higher than in the current study (51.6% susceptibility to erythromycin and 67.7% to trimethoprim/sulfamethoxazole). 16 Antimicrobial surveillance results in the literature are sparse for Croatia. In a report summarizing surveillance results presented at the 7th Pneumo Surveillance Summit for countries in Central and Eastern Europe, Ceyhan et al. 17 reported penicillin non-susceptibility of 23% for Croatia for invasive isolates from 2012 compared with a rate of 43% in the current study for isolates from 2014-16. Croatia participates in the European Antimicrobial Resistance Surveillance Network (EARS-Net), but only invasive isolates from blood and CSF are collected. 18 In 2015, penicillin non-susceptibility rates of 19.4% were reported for isolates from Croatia, compared with 22.9% in Bulgaria and 39.0% in Romania.
Antimicrobial use has been identified as a major driver of development of resistance. 19, 20 A comparison of national antibiotic use with the resistance patterns observed in the current study found some correlation: in a study of 42 countries in the broader European region, Serbia was ranked 11th for total antibiotic use whereas Croatia was ranked 20th and Bulgaria 23rd. 21 This order corresponded well to the resistance levels in these three countries seen in the current study. However, Romania did not fit the pattern, as it was ranked only 33rd in total antibiotic use, yet it was one of the two countries with the highest resistance rates in the current study. Other factors could potentially impact resistance among S. pneumoniae, including national vaccination programmes. 22 In Bulgaria, pneumococcal vaccination has been included in the national childhood immunization programme (free of charge) since 2010 and Croatia and Serbia's national vaccination programmes include only children in 'at risk' groups, whereas in Romania the vaccine is recommended but not funded by the national health system. 11, 17, 23 Antimicrobial susceptibility was higher and variability across countries was much less pronounced for H. influenzae than for S. pneumoniae. Susceptibility by CLSI criteria to amoxicillin/clavulanic acid, azithromycin, cefuroxime, ceftriaxone and the fluoroquinolones was 98% in all four countries. Ampicillin susceptibility varied more, ranging from 85.3% in Romania to 100% in Bulgaria. The higher rate of resistance to amoxicillin when compared with ampicillin for H. influenzae (Table 4) is surprising and may reflect a technical issue with determination of amoxicillin MICs. If only b-lactamase-producing isolates are considered as amoxicillin resistant, the proportion of amoxicillin-susceptible isolates would rise by 6.7% for isolates from Serbia and by 3.5% to 4.1% in the other three countries. However, the greatest variability was found not across countries but across breakpoints. For example, although susceptibility to azithromycin and cefuroxime using CLSI criteria was 98% in all four countries, susceptibility was 0% or 1% by EUCAST criteria. In the case of H. influenzae this is not a significant clinical concern because, as the CLSI notes, the results of susceptibility tests with these antimicrobial agents are often not useful for management of individual patients (although susceptibility testing may be appropriate for surveillance or epidemiological studies). 8 However, for other species differences between breakpoints make it very difficult for clinicians to interpret antimicrobial resistance data and to compare findings in the literature across regions and over time.
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The main limitation of this study stems from small sample sizes and the attempt to draw conclusions about a country's antimicrobial susceptibility levels using data from just one or two hospital sites. Surveillance results in the literature were also often limited to one hospital, 13, 15 underscoring the necessity for more widespread surveillance at more sites in each country. However, despite these limitations, patterns emerged that can be useful for clinicians in selecting empirical therapy for CAP, for example regarding the high rates of resistance to S. pneumoniae in Romania and Serbia. This variability in antimicrobial susceptibility found across the four neighbouring countries provides yet another motive to increase the monitoring and reporting of national and local resistance patterns. Such findings provide information critical for the selection of appropriate antimicrobial agents, especially when treatment is of necessity empirical, such as for CAP, and can improve national and local treatment guidelines.
